Carlos M de Castro
Overview
Explore the profile of Carlos M de Castro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Castro C, Patel B
Expert Opin Pharmacother
. 2024 Oct;
25(18):2331-2339.
PMID: 39404123
Introduction: Standard-of-care first-line treatments for paroxysmal nocturnal hemoglobinuria (PNH) include the anti-C5 therapies eculizumab and ravulizumab. However, persistent anemia, likely due to extravascular hemolysis, and reduced quality of life (QoL)...
2.
Babushok D, DeZern A, de Castro C, Rogers Z, Beenhouwer D, Broder M, et al.
Blood Adv
. 2024 Apr;
8(15):3946-3960.
PMID: 38669341
Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled...
3.
Peffault de Latour R, Roth A, Kulasekararaj A, Han B, Scheinberg P, Maciejewski J, et al.
N Engl J Med
. 2024 Mar;
390(11):994-1008.
PMID: 38477987
Background: Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors. Iptacopan,...
4.
Peffault de Latour R, Szer J, Weitz I, Roth A, Hochsmann B, Panse J, et al.
Lancet Haematol
. 2022 Sep;
9(9):e648-e659.
PMID: 36055332
Background: In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab...
5.
Greenberg P, Stone R, Al-Kali A, Bennett J, Borate U, Brunner A, et al.
J Natl Compr Canc Netw
. 2022 Feb;
20(2):106-117.
PMID: 35130502
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to...
6.
Troy J, de Castro C, Pupa M, Samsa G, Abernethy A, LeBlanc T
J Natl Compr Canc Netw
. 2018 Mar;
16(3):267-273.
PMID: 29523665
NCCN defines distress as a multifactorial, unpleasant emotional experience of a psychological nature that may interfere with patients' ability to cope with cancer symptoms and treatment. Patients with myelodysplastic syndromes...
7.
Greenberg P, Stone R, Al-Kali A, Barta S, Bejar R, Bennett J, et al.
J Natl Compr Canc Netw
. 2017 Jan;
15(1):60-87.
PMID: 28040720
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on...
8.
Griffin P, Komrokji R, de Castro C, Rizzieri D, Melchert M, List A, et al.
Am J Hematol
. 2015 Jun;
90(9):796-9.
PMID: 26089240
Older patients with acute myeloid leukemia (AML) have poor outcomes, with median durations of complete remission lasting less than 1 year. Increased toxicity in older patients limits the delivery of...
9.
Greenberg P, Stone R, Bejar R, Bennett J, Bloomfield C, Borate U, et al.
J Natl Compr Canc Netw
. 2015 Mar;
13(3):261-72.
PMID: 25736003
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore...
10.
Greenberg P, Attar E, Bennett J, Bloomfield C, Borate U, de Castro C, et al.
J Natl Compr Canc Netw
. 2013 Jul;
11(7):838-74.
PMID: 23847220
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid...